article thumbnail

FDA Approves Clesrovimab-cfor for Prevention of RSV in Infants

Drug Topics

“Enflonsia provides an important new preventive option to help protect healthy and at-risk infants born during or entering their first RSV season with the same dose regardless of weight,” Dean Y Li, president of Merck Research Laboratories, said in a release.

FDA 430
article thumbnail

FDA to Evaluate Merck’s Doravirine, Islatravir Regimen for HIV-1

Drug Topics

“Merck has been at the forefront of HIV research for more than 35 years and we are pleased to continue our work to innovate and deliver new options that aim to meet the needs of the HIV community,” Eliav Barr, senior vice president, head of global clinical development and chief medical officer at Merck Research Laboratories, said in a release.

FDA 247
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

MSD receives FDA approval for Enflonsia to prevent RSV

Pharmaceutical Technology

MSD research laboratories president Dean Li stated: “Enflonsia provides an important new preventive option to help protect healthy and at-risk infants born during or entering their first RSV season with the same dose regardless of weight.

FDA 52
article thumbnail

FDA to review MSD’s doravirine/islatravir NDA for HIV-1

Pharmaceutical Technology

MSD Research Laboratories global clinical development senior vice-president and head, chief medical officer Dr Eliav Barr stated: “MSD has been at the forefront of HIV research for more than 35 years and we are pleased to continue our work to innovate and deliver new options that aim to meet the needs of the HIV community.

FDA 52
article thumbnail

FDA approves MSD’s Keytruda to treat head and neck cancer

Pharmaceutical Technology

GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

FDA 52
article thumbnail

MSD bolsters US manufacturing capacity with $1b investment

European Pharmaceutical Review

Early clinical data have provided robust evidence for the potential of CN201 to target and deplete circulating and tissue B cells with the potential to treat a range of malignant and autoimmune diseases, Dr Dean Li, President, Merck Research Laboratories shared at the time of the acquisition announcement.

article thumbnail

MSD to advance investigational Lp(a) inhibitor in nearly $2b deal

European Pharmaceutical Review

Expanding treatment options for atherosclerosis with an Lp(a) inhibitor “The drug is an important addition that expands and complements our cardio-metabolic pipeline, remarked Dr Dean Li, President, Merck Research Laboratories.